We provide you with 20 years of free, institutional-grade data for MBRX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MBRX. Explore the full financial landscape of MBRX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Moleculin Biotech, Inc(NASDAQ:MBRX) 
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or r...
Website: http://www.moleculin.com
Founded: 2015
Full Time Employees: 11
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about MBRX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.